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Context: The increasing prevalence of obesity and diabetes greatly influences the risk for cardio-
vascular (CV) comorbidities and affects the quality of life of many people. However, the relationship
among diabetes, obesity, and cardiovascular risk is complex and requires further investigation to
understand the biological milieu connecting these conditions.
Objective: The aim of the current study was to explore the relationship between biological markers of
adipose tissue function (adiponectin) and CV risk (apolipoprotein B) in bodymass index (BMI)–matched
participants with and without diabetes.
Design: Nested case-control study.
Setting: The Atlantic Partnership for Tomorrow’s Health (PATH) cohort represents four Atlantic
Canadian provinces: Newfoundland and Labrador, New Brunswick; Nova Scotia; and Prince Edward
Island.
Participants: The study population (n = 480) was aged 35 to 69 years, 240 with diabetes and 240
without diabetes.
Main Outcome Measures: Groups with and without diabetes were matched for sex and BMI. Both
measured and self-reported data were used to examine disease status, adiposity, and lifestyle factors.
Immunoassays were used to measure plasma markers.
Results: In these participants, plasma adiponectin levels were lower among those with diabetes than
those without diabetes; these results were sex-specific, with a strong relationship seen in women. In
contrast, in participants matched for sex and adiposity, plasma apoB levels were similar between
participants with and those without diabetes.
Conclusion:Measures of adiposity were higher in participants with diabetes. However, whenmatched
for adiposity, the adipokine adiponectin exhibited a strong inverse association with diabetes.
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The global prevalence of diabetes continues to rise, and according to the World Health Or-
ganization, 422 million people worldwide had diabetes mellitus in 2014 [1]. The burden of
diabetes is of great concern because 1.5 million deaths are directly caused by diabetes [1].
Diabetes places a huge economic burden on the health care system and greatly affects an
individual’s quality of life [2, 3]. In Canada, diabetes affects approximately 7% of the pop-
ulation and is more prevalent in men than women older than age 45 years [4]. The Atlantic
Canada provinces have the highest proportion of residents living with diabetes in Canada [4].
Obesity is a risk factor for type 2 diabetes [5] and cardiovascular (CV) events, such as
myocardial infarction and stroke [6]. The common biological milieu and interconnectivity
among obesity, diabetes, and CV disease are not clear and require additional investigation.
Adipose tissue has functions that go beyond simply storing fat; it plays a fundamental role
as anendocrine organ, contributing to glucosehomeostasis, energybalance, and inflammation [7].
When energy substrates are consumed in excess of energy needs, the adipose tissue undergoes
hyperplasia and hypertrophy to accommodate the excess lipid. The pathological consequence of
adipose tissue expansion is inflammation in the fat tissue and increased inflammatory
cytokine secretion, which in turn is associatedwithmultiple cardiometabolic alterations [8].
Thus, the metabolic function and altered adipokine secretion from adipose tissue may be a
crucial factor contributing to CV risk in people with diabetes.
The adipokine adiponectin is produced and secreted by adipocytes and is found in cir-
culation at relatively high levels (~2 to 30 mg/mL) in healthy individuals [9, 10]. Recent work
has shown that adiponectin levels can be used to predict the progression of patients from
normoglycemia to prediabetes [11]. In addition, research over the past decade has
demonstrated a negative association between circulating adiponectin levels and obesity,
diabetes, and CV events [9, 12–15].
Guidelines to lower the risk for adverse CV events have emphasized the importance of
lowering low-density lipoprotein cholesterol levels. However, apolipoprotein B (apoB), the
main protein in triglyceride-rich very-low-density lipoprotein and low-density lipoprotein
particles, has been suggested as a superior measure of CV disease risk [16, 17]. Interestingly,
an inverse association has been reported between apoB and adiponectin concentrations in
men [18], and more recently apoB has been associated with increased glucose levels [19].
However, the relationship between adiponectin and apoB in women and those with diabetes
remains to be determined. Therefore, the aim of the current study was to explore the re-
lationship between serum markers of adipose tissue function (adiponectin) and CV risk
(apoB) in both obese and nonobese populations with and without diabetes.
1. Participants and Methods
A. Study Population and Data Collection
Details on recruitment and data collection have been previously described [20]. Participants
for a nested case-control study were derived from the Atlantic Partnership for Tomorrow’s
Health (PATH) cohort. All participants provided written informed consent before completing
any study-related procedures. Original data and sample collection procedures were approved
by the appropriate research ethics boards in each Atlantic Canada province (Nova Scotia,
New Brunswick, Newfoundland and Labrador, and Prince Edward Island). The Dalhousie
University Research Ethics Board approved the secondary analysis of biological samples.
Questionnaire data were collected from 31,174 participants aged 35 to 69 years who were
residents of the four Atlantic provinces between 2009 and 2015. Of these participants, 30,830
responded (yes or no) to ever being diagnosed with diabetes and 24,773 participants had data
on both diabetes and height and weight measures needed to calculate body mass index (BMI)
(Fig. 1).
To examine plasma markers of adiponectin and apoB in a subset of participants, we
conducted a case-control study nested within the Atlantic PATH cohort with matching to
increase study efficiency. Because participants with diabetes had higher measures of
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adiposity (Table 1) and adiposity is also a cofounder for adiponectin levels, a subset of
participants with diabetes was randomly selected and a control group without diabetes was
matched for BMI. In addition, because sex is known to influence plasma levels of adiponectin
[21] and apoB [22], the subgroups with or without diabetes also contained the same number of
men andwomen. Sample size calculationswere based on the number of participants needed to
observe significant differences in plasma adiponectin and apoB. On the basis of means and
standard deviations fromprevious studies [19, 23], ana value of 0.05 (two-sided), and power of
80%, the sample size for each group would be 165 to 237 participants to detect differences in
plasma apoB and adiponectin levels between those with and without diabetes. Thus, each
group was rounded up to 240 participants (ever diagnosed with diabetes, n = 240; never
diagnosed with diabetes, n = 240) and was matched for sex and BMI (60 men and 60 women
with BMI of 18.5 to 24.9 kg/m2and 60 men and 60 women with BMI of 30 to 42 kg/m2 in each
group) (Fig. 1).
B. Assessment of Disease and Lifestyle Risk Factors
The estimate of the diagnosed prevalence of diabetes and CV disease (higher blood pressure,
myocardial infarction, and stroke) was derived from self-reported information. Additional
questions related to lifestyle and behavior, including diet, smoking, alcohol consumption, and
education were assessed. The education level achieved was categorized as high school or
lower, college level (trade/community college), and university level or higher (university
certificate, bachelor’s and graduate degree). For smoking behavior, participants were cate-
gorized as current smoker, former smoker, and never smoker. For alcohol consumption,
participants were classified as an abstainer, occasional drinker (,3 times/month), regular
drinker (1 to 3 times/week), and habitual drinker (4 to 7 times/week). A set of food-frequency
questions were used to assess fruit and vegetable intake as well as calculate a healthy eating
index (HEI) score for each participant as previously described [20]. In brief, the HEI is a
Figure 1. Flow diagram showing sample selection for nested case-control study.
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continuous variable with a minimum score of 0 (indicating poorest dietary habits) and a
maximum score of 60 (indicating optimal dietary habits).
C. Assessment of Obesity and Body Composition
In the Atlantic PATH cohort, anthropometric indices, including height, weight, and waist
and hip circumference, were self-reported by participants; for some participants they were
Table 1. Characteristics of Matched Diabetic and Nondiabetic Participants
Characteristic Total Nondiabetic Diabetic P Value
Men (n) 240 120 120 1.000
Women (n) 240 120 120
Province, n (%) 0.275
Nova Scotia 270 (56.25) 145 (60.42) 125 (52.08)
New Brunswick 127 (26.46) 55 (22.92) 72 (30.00)
Newfoundland and Labrador 73 (15.21) 35 (14.58) 38 (15.83)
Prince Edward Island 10 (2.08) 5 (2.08) 5 (2.08)
Education, n (%) 0.619
High School or less 97 (20.34) 47 (19.75) 50 (20.92)
College level 194 (40.67) 93 (39.08) 101 (42.26)
University level 186 (38.99) 98 (41.18) 88 (36.82)
Waist-to-hip ratio, n (%)a 246 (54.73) 120 (52.86) 129 (56.58) 0.426
Abdominal obesity, n (%)b 197 (42.64) 94 (41.05) 103 (44.21) 0.492
BMI . 30 kg/m2, n (%) 237 (53.99) 118 (53.88) 119 (54.10) 0.640
CV variables, n (%)
High blood pressure 250 (52.1) 120 (50.00) 130 (54.17) 0.361
MI 23 (4.86) 8 (3.33) 15 (6.44) 0.117
Stroke 7 (1.48) 3 (1.25) 4 (1.71) 0.678
Statin use 173 (36.04) 186 (22.50) 121 (49.48) ,0.001
Smoking status 0.306
Never 228 (47.50) 121 (50.42) 107 (44.58)
Former 204 (42.50) 99 (41.25) 105 (43.75)
Current 48 (10.00) 20 (8.33) 28 (11.67)
Alcohol drinking ,0.001
Abstainer 71 (14.79) 24 (10.00) 47 (19.58)
Occasional drinker 220 (45.83) 104 (43.33) 116 (48.33)
Regular drinking 109 (22.71) 58 (24.17) 51 (21.25)
Habitual drinker 80 (16.67) 54 (22.50) 26 (10.83)
Fruits and vegetables (five a day) 207 (43.13) 105 (43.75) 102 (42.50) 0.782
Age (y) 55.37 6 8.38 54.28 6 8.68 56.45 6 7.94c 0.004
Height (cm) 165.46 6 8.44 165.92 6 8.51 165 6 8.36 0.232
Weight (km) 78.89 6 20.88 79.12 6 20.72 78.66 6 21.09 0.810
Waist (cm) 92.29 6 15.48 92.13 6 15.33 92.44 6 15.65 0.826
Hips (cm) 104.97 6 12.57 105.00 6 12.89 104.95 6 12.27 0.967
BMI (kg/m2) 28.70 6 6.78 28.64 6 6.80 28.75 6 6.77 0.857
Waist-to-hip ratio 0.89 6 0.09 0.88 6 0.08 0.88 6 0.09 0.747
Percentage fat mass 33.97 6 9.62 34.14 6 9.35 33.80 6 9.91 0.697
Fat mass index (kg/m2) 10.17 6 4.99 10.14 6 5.01 10.20 6 6.13 0.912
BMI at age 18 y (kg/m2) 23.86 6 6.00 23.36 6 5.85 24.35 6 6.13 0.210
Change in BMI from age 18 y (kg/m2) 2.29 6 7.29 3.18 6 7.32 1.43 6 7.18 0.068
Vegetable intake (servings/d) 2.30 6 1.41 2.35 6 1.40 2.26 6 1.41 0.507
Fruit intake (servings/d) 2.03 6 1.31 2.08 6 1.38 1.98 6 1.24 0.409
Healthy eating index 39.13 6 8.60 39.59 6 8.42 38.67 6 8.78 0.388
Adiponectin (mg/mL) 7.33 6 5.57 7.88 6 6.19 6.78 6 4.81c 0.030
apoB (mg/dL) 62.67 6 22.64 62.67 6 22.95 62.66 6 22.37 0.996
Values expressed with a plus/minus sign are the mean 6 standard deviation.
Abbreviation: MI, myocardial infarction.
aWaist-to-hip ratio .0.9 for men and .0.85 for women.
bWaist circumference $102 cm for men and $88 cm for women.
cP , 0.01.
1480 | Journal of the Endocrine Society | doi: 10.1210/js.2017-00339
measured in an assessment center by research nurses. In the nested case-control study, all
participants had measured BMI data and 88% had measured waist circumference and waist-
to-hip ratio data. Only when measured anthropometric indexes were unavailable were self-
reported anthropometric data used to calculate abdominal obesity and waist-to-hip ratio
above guidelines. Participants with a BMI of,18.5, 18.5 to 24.9, 25.0 to 29.9 and.30.0 kg/m2
were considered underweight, normal weight, overweight, and obese, respectively. Thewaist-
to-hip ratio was set at .0.90 for men and .0.85 for women [24]. Abdominal obesity was
defined as having a waist circumference $102 cm for men and $88 cm for women [20, 24].
Tanita Segmental Body Composition Analyzer was used to assess body composition by
bioelectrical impedance for participants who visited an assessment center. The fat mass and
fat-free mass indices were calculated by dividing fat mass and fat-free mass by height in
meters squared, respectively [25].
D. Biological Samples and Analysis of Plasma Proteins
Blood samples were collected by a phlebotomist on a subgroup of 21,160 participants who
visited an assessment center. Samples were shipped, divided into aliquots, and stored in
CryoTubes (Sarstedt) in280°C freezers at the processing laboratories within 24 to 48 hours of
being collected. Blood samples for plasma preparation were collected in tubes containing
EDTA and were separated by centrifugation at 1500g for 10 minutes. Plasma levels of
adiponectinweremeasuredwith amagnetic bead-based immunoassay (Bio-Plex Pro, Bio-Rad
Laboratories, #171A7003M). Data were captured on the Bio-Plex 200 system and analyzed in
duplicate using the Bio-Plex Manger 6.0 software (BioRad). Plasma levels of apoB were
analyzed by an enzyme-linked immunosorbent assay (R&D Systems, #DAPBOO) and
microplate reader, following manufacturer’s instructions.
E. Statistical Analysis
Data analyses were performed with IBM SPSS Statistics (version 22) software. Continuous
variables were presented as mean 6 standard deviation. Categorical variables were pre-
sented as counts (percentages). Significant associations between participants with or without
diabetes and demographic, behavioral, and adiposity measures and CV events were de-
termined by x2 analysis. Differences in anthropometric measures and plasma markers be-
tween participants with and without diabetes were analyzed by using an unpaired t test. To
address the impact of statin medication on plasma markers, a sensitivity analysis was
performed by removing all participants taking statins from the analysis. For continuous
variables, the comparison of four groups (men, women, diabetes, no diabetes) was performed
by using a two-way analysis of variance. The relationship between adiponectin and apoB
concentrations with anthropometric measures was analyzed by using Pearson correlation
coefficients. Logistic regression models were used to assess adiponectin or apoB as predictors
of the prevalence of diabetes. Variables in the predictivemodels that had aP value,0.05 (age
and alcohol use) were retained in the final model. The association between diabetes and each
plasma marker is presented by odds ratios with 95% confidence intervals.
2. Results
Overall, 7.6% of the participants (7.14% of women and 8.67% of men) in the Atlantic PATH
cohort indicated that they had been diagnosed with diabetes (Supplemental Table 1). Because
participants with diabetes in the Atlantic PATH cohort had higher reported measures of
adiposity (Supplemental Table 1), a subset of participants was matched for BMI (Table 1) to
examine plasma markers of adiponectin and apoB in participants with and without diabetes.
In the nested case-control study participants (n = 480), the prevalence of CV disease and
lifestyle factors, such as smoking status and diet quality, were similar between participants
with and without diabetes (Table 1). The overall prevalence of high blood pressure,
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myocardial infarction, and stroke was 52.1%, 4.7%, and 1.5%, respectively. The prevalence
of abdominal obesity and a waist-to-hip ratio above guidelines was similar between those
with and those without diabetes (Table 1). Overall, 36% of participants reported taking
statins, and this percentage was higher in patients with diabetes than in those without
diabetes (Table 1).
Levels of apoB were similar between participants with and without diabetes; however,
adiponectin levels were higher in participants without diabetes than in those with diabetes
(Table 1). When participants currently taking statins were removed from the analysis, apoB
concentrations did not differ between those with diabetes and those without (64.5 mg/dL vs
62.4 mg/dL, respectively). To explore variation in plasma markers between sexes, levels of
apoB and adiponectin in participants with and without diabetes were analyzed separately in
bothmen and women. Levels of apoBwere similar betweenmenwith and without diabetes as
well as inwomen [Fig. 2(A)]. In contrast, plasma adiponectin levels were 1.44mg/mL higher in
women compared with men [Fig. 2(B)]. Plasma adiponectin levels were similar between men
with and without diabetes, whereas levels in women with diabetes were 1.88 mg/mL lower
than in women without diabetes [Fig. 2(B)].
The relationship between plasma adiponectin or apoB concentrations and anthropometric
variables was analyzed by using Pearson correlation coefficients. A weak-positive association
was found between adiponectin levels and plasma apoB levels (Table 2). A weak-positive
association was also found between plasma apoB levels and HEI and plasma adiponectin
levels (Table 2). Because plasma adiponectin levels were clearly different between partici-
pants with and without diabetes (Table 1 and Table 2), we used logistic regression models to
explore the relationship between adiponectin levels and diabetes. Plasma adiponectin levels
were inversely associated with diabetes (Table 3). This relationship remained after ad-
justment for age, education, smoking, alcohol use, and intake of five fruits and/or vegetables
per day (Table 3). In the sex-specific analysis, the association was apparent only in women in
both unadjusted and adjusted models (Table 3). We also divided participants into tertiles
according to plasma adiponectin levels and used logistic regression to estimate the re-
lationship between lower levels of adiponectin (the lowest adiponectin tertile, adipo-
nectin ,3.85 mg/mL) and the risk for diabetes. Overall there was a trend toward an
association. However, stratified analysis showed that the inverse association between the
lowest adiponectin tertile and diabetes prevalence was pronounced only for women (Sup-
plemental Table 2). By contrast, there was no association between plasma apoB levels and
diabetes (Table 3; Supplemental Table 2).
Figure 2. Scatterplot showing plasma apoB (A) and adiponectin (B) levels in diabetic or
nondiabetic men and women. Data are presented as mean 6 standard deviation (n = 120 per
group). Data were analyzed by using a two-way analysis of variance with the main effects of
sex and diabetes and, if justified, by Tukey multiple comparisons test. *P , 0.05. Black
symbols represent individual data points and red bars represent means 6 standard
deviation.
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3. Discussion
As the prevalence of obesity and diabetes continue to rise, there is a need for a greater
understanding of the interconnectivity among these conditions and CV disease risk. This
study characterizes members of the Atlantic PATH cohort with or without diabetes and
explores the relationship between the serum markers adiponectin and apoB in a sub-
sample of these two groups. There were clear differences in adiposity measures and CV
events between participants with and without diabetes in the overall Atlantic PATH
cohort. In a subset of 480 participants matched for sex and adiposity, plasma apoB levels
were similar between participants with and without diabetes; however, plasma adipo-
nectin levels were lower in participants with diabetes than in those without diabetes.
Further investigation indicated that an inverse association between plasma adiponectin
levels and the prevalence of diabetes was sex-specific, with a strong relationship apparent
only in women.
BMI is an estimate of overall adiposity but does not assess body fat distribution or
composition. In the current study, we included measures of waist circumference, waist-to-hip
ratio, and fat mass to estimate body fat distribution and composition. In agreement with
previous research [26] in a similarly aged population that used magnetic resonance imaging
to assess body composition and adipose mass distribution, we observed increased adipose
Table 2. Associations of Adiponectin and apoB with Age and Anthropometric Variables
Variable
Adiponectin apoB
R P Value R P Value
Age 20.051 0.143 0.042 0.189
Waist in cm 20.02 0.335 20.031 0.256
Waist-to-hip ratio 0.031 0.258 20.009 0.425
BMI in kg/m2 0.032 0.248 20.002 0.486
Percentage fat mass 0.006 0.453 0.044 0.174
Fat mass index in kg/m2 0.018 0.355 0.024 0.308
Healthy eating index 0.026 0.343 0.107 0.045
Plasma apoB and adiponectin 0.078 0.050 0.078 0.050
Unless otherwise noted, results are expressed as Pearson correlation coefficients. Boldface indicates statistical
significance (P # 0.05).
Table 3. Logistic Regression Models of Adiponectin and apoB with Diabetes
Variable
Adiponectin apoB
Odds Ratio (95% CI) P Value Odds Ratio (95% CI) P Value
Total
Unadjusted 0.964 (0.933–0.997) 0.032 1.000 (0.992–1.008) 0.996
Model 1 0.966 (0.934–0.999) 0.043 1.000 (0.992–1.008) 0.916
Model 2 0.959 (0.925–0.993) 0.018 0.999 (0.991–1.007) 0.828
Men
Unadjusted 0.986 (0.934–1.040) 0.596 0.996 (0.985–1.007) 0.478
Model 1 0.989 (0.937–1.045) 0.704 0.995 (0.984–1.007) 0.436
Model 2 0.971 (0.916–1.029) 0.317 0.993 (0.981–1.005) 0.257
Women
Unadjusted 0.950 (0.909–0.993) 0.022 1.004 (0.993–1.015) 0.483
Model 1 0.950 (0.909–0.993) 0.023 1.004 (0.992–1.015) 0.524
Model 2 0.951 (0.909–0.995) 0.028 1.004 (0.993–1.016) 0.476
Model 1: adjusted for age; model 2: adjusted for age and alcohol use.
Abbreviation: CI, confidence interval.
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mass (measured by bioelectrical impedance) and higher abdominal adipose in participants
with diabetes compared with those without diabetes. Likewise, we observed greater ab-
dominal adipose tissue mass in women (data not shown).
There is some controversy in the literature regarding abdominal obesity or percentage body
fat as better predictors than BMI for quantifying CV risk [27–31]. On the other hand, BMI
may bemore strongly associatedwith adipokine status thanmeasures of waist circumference,
waist-to-hip ratio, and percentage body fat [32]. Altered levels of adipokines are closely
related to obesity-related metabolic complications [33]. Adipose tissue serves as an active
endocrine organ, secreting a variety of adipokines that regulate energy intake, energy ex-
penditure, and endocrine function [34]. The adipokine adiponectin is of particular interest
with respect to obesity, diabetes, and CV risk [9, 12–15]. With the development of obesity,
adipose tissue mass increases by first enlarging in size, then by storing more lipids as tri-
acylglycerols; adipocyte numbers then increase to accommodate excess lipids. Data in pre-
clinical models and cultured adipocytes demonstrate that adiponectin levels may be altered
long before the amount of lipid in the adipocytes changes [35, 36].
Plasma adiponectin levels and insulin resistance are both independent predictors of very-
low-density lipoprotein apoB concentrations in men, although likely through different
mechanisms [18]. In addition,menwith higher apoB levels (.87mg/dL) have a higher risk for
diabetes [19]. In contrast, we did not observe any difference in apoB concentrations between
participants with and those without diabetes in the current study. However, this may be
because only 13% of participants in the current study had plasma apoB values.87 mg/dL. In
addition, wemust acknowledge differences in the populations, ethnicity, sex, andmethods for
examining apoB levels between the current study and previous reports. Future studies with
more detailed information on participant health status (such as progression and duration of
disease) may be useful in exploring the relationship between changes in plasma apoB levels
and diabetes progression.
Even obese individuals who are considered to have a “metabolically healthy” phenotype
(absence of metabolic abnormalities such as dyslipidemia, insulin resistance, and hy-
pertension) are at an increased risk for CV events [37]. Furthermore, metabolically
healthy individuals often progress to an unhealthy state or develop disease [38, 39]. Thus,
it may be useful to consider measuring other circulating markers, such as adiponectin, to
indicate early tissue dysfunction and risk for disease development. The changes in
markers of CV risk such as apoB levels may not occur until a later time point, once the
ability of adipose tissue has become overwhelmed and the liver starts to deal with the
excess lipids in the body. Future research should examine baseline plasma values and
incidence of disease over time (follow-up study). Participants in the Atlantic PATH cohort
will be followed for 30 years, which will provide an excellent opportunity to explore some of
these relationships over time.
The use of objectively measured anthropometric variables on most participants and a
large sample size are major strengths of the Atlantic PATH cohort. A limitation of the
current study is that the current use of medications was not considered before the case-
control sample nested within the cohort was examined. Although statin use was considered
in the sensitivity analysis and even after removal of those currently taking statins, no
difference was found in those with diabetes compared with those without. Perhaps not that
surprising given that previous research has shown that not all individuals respond to statin
therapy with respect to achieving optimal apoB levels [40]. Nonetheless, future studies
should explore the use of not only statins but other medications that may influence plasma
adiponectin and apoB levels in these populations. Future research should also focus on age
and changes in adipose depot distribution (e.g., intra-abdominal fat). Interestingly, adi-
ponectin levels appear to increase with age, and with increasing age body composition
changes: Lean mass declines whereas fat mass increases, resulting in an overall reduction
in metabolically active tissues and altered fat distribution [32, 41, 42]. Finally, more re-
search is needed to understand the influence of disease progression relative to circulating
plasma markers and measures of adiposity.
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4. Conclusions
In summary, we examined an important relationship between two plasma markers of
metabolic risk in a subsample of participants with and without diabetes in the Atlantic PATH
cohort. This study demonstrates that participants in the Atlantic PATH cohort with diabetes
have a higher prevalence of obesity (BMI. 30 kg/m2), abdominal obesity, and percentage fat
mass as well as a higher prevalence of CV events. In the case-control study nested within the
cohort, participants with similar levels of obesity and prevalence of CV events, plasma
adiponectin was lower in participants with diabetes than those without diabetes. In con-
clusion, adiponectin appears to be a unique marker of adipocyte function that exhibits a
strong inverse association with diabetes. Further research is needed to explore othermarkers
and mechanisms that may further improve our understanding of diabetes.
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